Doxazosin treatment in normotensive and hypertensive patients with benign prostatic hyperplasia

Talat Yurdakul, Giray Karalezli, Bülent Yiğit

  • Year : 1998
  • Vol : 14
  • No : 4
  •  Page : 155-158
Normotensive (group l) (n-21) and pharmacologically normotensive (group Il) (n=13) patients with benign prostate hypertrophy (BPH) are included in a survey for efficacy of doxazosin, which is a selective alpha-1 bloc-ker. The effects of doxazosin on urinary flow rates, International Prostate Symptom Score (IPSS), residual urine volume and blood pressure are evaluated. Doxazosin was giyen 4 mg for 12 weeks after a titration period of 3 weeks. Differences were found statistically significant in all parameters. In both groups, doxazosin caused a sta-tistically significant reduction in diastolic blood pressure but this was clinically unimportant. Side effects were to-lerated well by the patients. When medical treatment is indicated in normotensive and pharmacologically nor-motensive BPH patients, doxazosin can be used without significant blood pressure reduction.
Cite this Article As :
Description : None of the authors, any product mentioned in this article, does not have a material interest in the device or drug. Research, not supported by any external organization. grant full access to the primary data and, if requested by the magazine they agree to allow the examination of data.
Doxazosin treatment in normotensive and hypertensive patients with benign prostatic hyperplasia
, Vol. 14 (4)
Received : 10.10.1998, Accepted : 10.10.1998, Published Online : 06.10.2020
Selçuk Tıp Dergisi
ISSN:1017-6616;
E-ISSN:2149-8059;